Methotrexate is not a biologic. It is a conventional synthetic disease-modifying antirheumatic drug (DMARD), meaning it is chemically manufactured rather than produced from living cells. Despite being used to treat many of the same conditions as biologics, methotrexate belongs to a fundamentally different drug category, and the two are often prescribed together for better results.
What Makes a Drug a Biologic
The distinction comes down to how the drug is made and what it looks like at a molecular level. Biologics are large, complex protein molecules produced by living systems, either microorganisms or mammalian cells. They can contain hundreds of amino acids and have an inherently variable structure that current technology cannot fully characterize. Their production process yields relatively small quantities and is difficult to standardize.
Methotrexate, by contrast, is a small molecule created through chemical synthesis. It has a well-defined, uniform structure and can be produced in large, consistent batches. This is the same basic manufacturing approach used for most conventional medications. The molecular simplicity of methotrexate is part of the reason it costs a fraction of what biologics do and can be taken as a pill, while biologics must be injected or infused because their large protein structures would be destroyed by digestion.
How Methotrexate Works Differently
Biologics are engineered proteins that target specific parts of the immune system outside of cells. They block individual inflammatory signals, immune cells, or communication pathways with high precision. Each biologic is designed to intercept a particular molecule or receptor involved in the inflammatory cascade.
Methotrexate takes a broader approach. It blocks an enzyme critical for cell survival and division by interfering with folic acid metabolism. This slows down the rapidly dividing immune cells that drive inflammation. Because it affects a basic cellular process rather than a single immune signal, methotrexate has wider-reaching effects on the immune system, which is why folic acid supplements are typically recommended alongside it to offset some of those effects.
Cost Differences
The price gap between methotrexate and biologics is enormous. Generic oral methotrexate costs roughly $1.89 per dose, according to Medicare data. Meanwhile, common biologics like adalimumab and etanercept carried actual annual costs exceeding $56,000 to $58,000 as of 2017. Overall, drug costs for patients on conventional DMARDs like methotrexate run about $1,500 to $2,000 per year, compared to as much as $30,000 per year for patients on biologics. That gap is a major reason methotrexate remains the standard first-line treatment for conditions like rheumatoid arthritis.
How Each One Is Taken
Methotrexate is typically taken once per week, either as a pill or a subcutaneous injection. A common starting dose is 15 mg weekly, which can be adjusted upward if the response is insufficient. Both oral and injectable forms are considered roughly equivalent in effectiveness for rheumatoid arthritis, though the injectable version may cause less nausea and is sometimes better absorbed at higher doses.
Biologics are given by injection or intravenous infusion, with schedules ranging from twice weekly to once every several months depending on the specific drug. None of them can be taken orally. The need for injections or infusions, combined with the cost, makes biologics a second-line option for most patients.
Side Effects Compared to Biologics
Methotrexate’s most common side effects stem from its interference with folic acid metabolism: nausea, fatigue, mouth sores, and in rare cases, liver or lung problems with long-term use. These effects are generally manageable and well-studied after decades of clinical use.
Biologics carry a different risk profile. Because they suppress specific immune pathways, they increase the risk of infections, including serious bacterial, fungal, and opportunistic infections. A large Cochrane analysis found that biologics as a group were associated with a 37% higher rate of serious infections compared to control treatments. Certain biologics also carry a significantly elevated risk of tuberculosis reactivation, nearly five times higher than control. Infusion reactions and injection site reactions are also common with biologics.
Why Methotrexate Is Often Paired With Biologics
One of the more important things to understand about methotrexate is that even when a biologic is prescribed, methotrexate frequently stays in the picture. This is not just because the two drugs attack inflammation through different mechanisms. Methotrexate actually makes biologics work better by reducing the body’s tendency to develop antibodies against them.
Because biologics are large foreign proteins, the immune system can learn to recognize and neutralize them over time. When this happens, the biologic gets cleared from the bloodstream faster and loses effectiveness. Methotrexate suppresses this antibody response. In studies of adalimumab, adding methotrexate reduced the drug’s clearance rate by about 30%, keeping blood levels higher and more stable. This translates to better long-term disease control and a lower chance of the biologic simply stopping to work after months or years of use.
This pairing is one reason the two drug categories are so often discussed together, and possibly why the question of whether methotrexate is a biologic comes up so frequently. They are distinct types of medication that happen to work particularly well as a team.